Refine
Year of publication
Document Type
- Article (348) (remove)
Language
- English (348)
Has Fulltext
- yes (348)
Is part of the Bibliography
- no (348)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (5)
- Jets (5)
- Collective Flow (4)
- Heavy Quark Production (4)
- Quark-Gluon Plasma (4)
- Jets and Jet Substructure (3)
- Cancer genomics (2)
Institute
- Physik (340)
- Frankfurt Institute for Advanced Studies (FIAS) (281)
- Informatik (246)
- Medizin (5)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- ELEMENTS (1)
- Institut für Ökologie, Evolution und Diversität (1)
- Pharmazie (1)
- Psychologie (1)
- Sonderforschungsbereiche / Forschungskollegs (1)
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.